CASTLE BIOSCIENCES INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M |
| Cost of revenue | $71.0M | $60.2M | $45.0M | $32.0M | $15.8M |
| Selling, general & administrative | $229.3M | $200.0M | $180.2M | $143.0M | $86.7M |
| Research and development | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M |
| Operating income | -$42.8M | $8.7M | -$68.0M | -$72.9M | -$40.1M |
| Interest expense | $86,000 | $577,000 | $11,000 | $17,000 | $1,000 |
| Income tax expense | -$5.4M | $3.3M | $101,000 | -$1.8M | -$8.7M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M |
| Balance Sheet | |||||
| Cash and equivalents | $116.7M | $119.7M | $98.8M | $122.9M | $329.6M |
| Current assets | $361.1M | $360.2M | $295.6M | $292.3M | $353.7M |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M |
| Current liabilities | $68.7M | $49.4M | $47.7M | $36.1M | $24.9M |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M |
| Total debt | $10.2M | $10.2M | — | — | — |
| Stockholders' equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M |
| Cash Flow Statement | |||||
| Cash from operations | $64.3M | $64.9M | -$5.6M | -$41.7M | -$19.0M |
| Depreciation and amortization | $40.8M | $16.0M | $12.3M | $10.5M | $3.4M |
| Stock-based compensation | $45.9M | $50.3M | $51.2M | $36.3M | $21.7M |
| Capital expenditure | $36.0M | $28.3M | $13.6M | $5.6M | $3.5M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M | -$22.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 30.3M · Free float 95.0%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.